What is NxGen MDx?
Founded in 2012, NxGen MDx specializes in genetic screening technologies, leveraging next-generation sequencing to achieve over 99% accuracy in clinical detection rates for a wide array of conditions. The company's proprietary approach analyzes entire coding regions of genes, offering a more comprehensive assessment of genetic risk compared to abbreviated sequencing or genotyping methods used by competitors. This advanced technique ensures the detection of pathogenic variants that might otherwise be missed, providing individuals with a more accurate understanding of their health predispositions and enabling better-informed decisions for themselves and their families.
How much funding has NxGen MDx raised?
NxGen MDx has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for NxGen MDx?
The recent major strategic investment into NxGen MDx, following a period of significant enterprise-level funding, indicates a strong market confidence in the company's innovative genetic screening solutions. This capital injection is expected to fuel further technological development, enhance market penetration, and potentially expand the company's service offerings. NxGen MDx is strategically positioned to capitalize on the growing demand for precise and comprehensive genetic diagnostics, aiming to improve patient outcomes through early and accurate risk identification.
See full NxGen MDx company page
